Tumour-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: a preliminary report (National Cancer Institute)
N = 20
- Population
- 20 patients with metastatic melanoma: 15 not previously treated with interleukin-2 and 5 in whom previous interleukin-2 therapy had failed.
- Design
- Uncontrolled series of patients treated with adoptive transfer of autologous tumour-infiltrating lymphocytes (expanded in vitro from resected melanoma) and interleukin-2, after a single intravenous dose of cyclophosphamide. Treatment course lasted five days (per the abstract).
- Arms
- TIL plus interleukin-2 (experimental, n = 20): Single intravenous dose of cyclophosphamide, then autologous tumour-infiltrating lymphocytes and interleukin-2
- People
- Rosenberg SA, senior author Seipp CA, National Cancer Institute (Surgery Branch, Bethesda, per the PubMed affiliation of the first author)
Show the numbers
| Endpoint | Analysis | TIL plus interleukin-2 | Control | Effect |
|---|---|---|---|---|
| ORRPatients not previously treated with interleukin-2 (9 of 15 had objective regression)Objective regression of the cancer, as reported in 1988 (the abstract does not name response criteria) | primaryRosenberg 1988 | 60% | — | Regression occurred in lung, liver, bone, skin and subcutaneous sites and lasted from 2 to more than 13 months (all 11 responders in the series). |
| ORRPatients in whom previous interleukin-2 therapy had failed (2 of 5 had objective regression)Objective regression of the cancer, as reported in 1988 (the abstract does not name response criteria) | primaryRosenberg 1988 | 40% | — | — |
| Endpoint | Analysis | TIL plus interleukin-2 | Control | Effect |
|---|---|---|---|---|
| ORRPatients not previously treated with interleukin-2 (9 of 15 had objective regression)Objective regression of the cancer, as reported in 1988 (the abstract does not name response criteria) | primaryRosenberg 1988 | 60% | — | Regression occurred in lung, liver, bone, skin and subcutaneous sites and lasted from 2 to more than 13 months (all 11 responders in the series). |
| ORRPatients in whom previous interleukin-2 therapy had failed (2 of 5 had objective regression)Objective regression of the cancer, as reported in 1988 (the abstract does not name response criteria) | primaryRosenberg 1988 | 40% | — | — |